Society for Investigative Dermatology

Jared Gollob, MD, chief medical officer at Kymera Therapeutics, discusses early efficacy signals, the phase 2b study design, and the potential clinical role of KT-621, an oral STAT6 degrader, for moderate to severe atopic dermatitis.

Jared Gollob, MD, chief medical officer at Kymera Therapeutics, reviews phase 1b data for KT-621, an oral STAT6 degrader being evaluated for atopic dermatitis.

Jared Gollob, MD, discusses phase 1b biomarker findings for KT-621, a STAT6 degrader in atopic dermatitis, presented at SID 2026.

Albert Chiou, MD, MBA, reviews updates presented at SID 2026 on phase 1 data showing soquelitinib activity in prior systemic therapy failures, with a well-balanced adverse event profile vs placebo.

Albert Chiou, MD, MBA, discusses results from the phase 1 trial of soquelitinib for moderate to severe AD presented at SID 2026.

Treatment discontinuations due to laboratory abnormalities were uncommon, occurring in 0.7% of patients at week 52 and remaining below 2% through week 140.

Phase 2 TOIVA data show Palvella's QTORIN rapamycin reduces bleeding and improves quality of life in cutaneous venous malformations, addressing an unmet treatment need.

Recent posters at SID revealed significant increases in psoriasis and cellulitis cases in the US, highlighting urgent needs for prevention and treatment strategies.

Biologics significantly lower cardiovascular risks in psoriasis patients on statins, highlighting their dual benefits for skin and heart health.

Extended oral corticosteroid therapy in patients with atopic dermatitis significantly increases cardiovascular and thrombotic risks, urging careful treatment evaluations.

Researchers reveal TRIV-509, a novel monoclonal antibody, shows promise in rapidly improving atopic dermatitis by restoring skin barrier integrity and reducing inflammation.

Selective ITK inhibition with oral soquelitinib led to early and durable clinical responses, cytokine reduction, and increased T regulatory cells.